Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Sarcoma
Join Suzanne George, MD and Chandrajit P. Raut, MD, MSc from Dana-Farber Cancer Institute as they present their expertise on a range of cases pertaining to sarcoma.
Sarcomas constitute a heterogeneous group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathologic features. They can develop in soft tissue (including fat, muscle, nerve and nerve sheath, blood vessels, and other connective tissues) or in bone. Soft-tissue sarcoma most commonly metastasizes to the lungs; tumors arising in the abdominal cavity more commonly metastasize to the liver and peritoneum.
Treatment approach for soft-tissue sarcoma is determined by tumor type and extent of disease. Clinicians should have knowledge of combination and single-agent systemic therapy regimens with demonstrated efficacy against specific histologic subtypes of soft-tissue sarcoma. Additionally, clinicians should be aware of developing clinical trial data and recent FDA drug approvals for treating soft-tissue sarcoma.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Select an optimal treatment approach and sequence when reviewing potential medical, radiologic, and/or surgical options for treatment of soft-tissue sarcoma.
- Evaluate the clinical evidence base for current and emerging systemic therapies for treating soft-tissue sarcoma.
- Review the data from developing clinical trials in soft-tissue sarcoma.
Suzanne George, MD
Dana-Farber Cancer Institute
Chandrajit P. Raut, MD, MSc
Brigham and Women’s Hospital
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below has no relevant financial relationships to disclose:
Chandrajit P. Raut, MD, MSc
The faculty listed below have disclosed the following relevant financial relationships:
Suzanne George, MD
Ariad Pharmaceuticals, Inc: Grant/Research Support
Bayer HealthCare: Grant/Research Support
Blueprint Medicines: Grant/Research Support
Deciphera: Grant/Research Support
Novartis: Grant/Research Support
Pfizer Inc.: Grant/Research Support
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary Anne Bergman; Jillian L. Scavone, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.85 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-083-H01-P
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.85 ANCC contact hours
- 0.75 Participation